secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immix Biopharma, Inc. (IMMX)
CIK:        0001873835
Form:       8-K
Filed at:   2024-05-20T23:59:59+00:00
Accession:  0001493152-24-020785
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immix Biopharma completes short-form merger of majority-owned subsidiary Nexcella
--------------------------------------------------------------------------------

- On May 20, 2024, Immix merged its >95%-owned subsidiary Nexcella into itself; Nexcella ceased to exist.
- Issued 989,876 shares of common stock to former Nexcella stockholders (including third-party cash investors).
- Issued 275,759 restricted stock awards and options to purchase 595,676 shares at $2.47 per share to former Nexcella equity plan participants.
- Nexcella stockholders have appraisal rights under Delaware law if they perfect them.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873835/000149315224020785/0001493152-24-020785-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873835/000149315224020785/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-020785

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer